Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote & News

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 659 8001

Website: www.rocketpharma.com

Address:

9 Cedarbrook Drive, Cranbury, United States

tovlee Jun. 18 at 1:43 AM

$RCKT at least $10 by end of the year.

0 · Reply

topstockalerts Jun. 17 at 7:26 PM

$RCKT what looked ordinary this morning no longer does.

0 · Reply

iQuicky Jun. 17 at 5:57 PM

$INDP $CVKD $ARTV $REPL $RCKT investing in their future!

0 · Reply

Stephanovich7654568 Jun. 17 at 5:40 PM

$RCKT Blackrock is one of the biggest investment firm in USA. They are now the second largest holder of RCKT. They don't play with their money. They know what they are doing. 😉

1 · Reply

xXCronoSXx Jun. 17 at 4:47 PM

$RCKT

0 · Reply

geegor Jun. 17 at 4:03 PM

$RCKT large order inflows. Big fish loading.

0 · Reply

Cautiousamphybian Jun. 17 at 3:25 PM

$RCKT This is annoying. I'd only built about 10% of the position I wanted and have no idea why the share price is climbing so much today, seemingly no news. Anyone have any ideas?

4 · Reply

Diverstj981 Jun. 17 at 3:04 PM

$RCKT

0 · Reply

Wolfietrader Jun. 17 at 2:41 PM

$RCKT whu….huh?

0 · Reply

JunkPost Jun. 16 at 6:19 PM

$RCKT Upcoming catalyst:- 1) Danon disease gene therapy (RP-A501) – Phase 2 update (H2 2026) 2) BAG3 cardiomyopathy (RP-A701) – first patient dosing (mid-2026) 3) Kresladi commercialization ramp (post-approval execution) 4) Cash runway stability (through ~2028) $180M PRV sale materially strengthened balance sheet Catalyst implication: reduces near-term dilution pressure supports multi-year trial execution runway 5) Potential financing or partnership news (2026–2027)

1 · Reply

Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M

Jun 12, 2026, 7:00 AM EDT - 5 days ago

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Jun 9, 2026, 10:00 AM EDT - 8 days ago

Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:10 AM EDT - 13 days ago

Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T15:27:07.000Z - 14 days ago

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

May 28, 2026, 7:00 AM EDT - 20 days ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 20, 2026, 9:00 AM EDT - 4 weeks ago

Rocket Pharmaceuticals Transcript: AGM 2026

2026-05-07T21:49:50.000Z - 5 weeks ago

Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

May 7, 2026, 4:00 PM EDT - 5 weeks ago

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026, 7:00 AM EDT - 5 weeks ago

Rocket Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 5 weeks ago

Rocket Pharmaceuticals Earnings release: Q1 2026

2026-04-28T11:29:11.000Z - 7 weeks ago

Rocket Pharmaceuticals announces $180M sale of priority review voucher

Apr 28, 2026, 7:00 AM EDT - 7 weeks ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

2026-03-30T10:30:11.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

2026-03-27T19:15:17.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

2026-03-27T16:13:26.000Z - 2 months ago

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

2026-03-27T16:10:33.000Z - 2 months ago

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

Mar 27, 2026, 8:30 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 2 months ago

Rocket Pharmaceuticals Press release: FDA announcement

Mar 27, 2026, 7:27 AM EDT - 2 months ago

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

2026-03-27T11:05:10.000Z - 2 months ago

Rocket Pharmaceuticals announces FDA approval of Kresladi

Mar 27, 2026, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

2026-03-27T00:55:09.000Z - 2 months ago

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

2026-03-10T21:40:14.000Z - 3 months ago

Rocket Pharmaceuticals offers to sell up to $100M in common stock

Mar 10, 2026, 9:20 AM EDT - 3 months ago

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-02T21:21:06.000Z - 3 months ago

Rocket Pharmaceuticals files $400M mixed securities shelf

Mar 2, 2026, 11:10 AM EST - 3 months ago

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 3 months ago

Rocket Pharmaceuticals Registration statement: Registration Filing

2026-03-02T11:54:20.000Z - 3 months ago

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

2026-02-27T15:05:34.000Z - 3 months ago

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

2026-02-26T21:17:28.000Z - 3 months ago

Rocket Pharmaceuticals reports Q4 EPS (38c), consensus (42c)

Feb 26, 2026, 4:00 PM EST - 3 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Feb 26, 2026, 7:00 AM EST - 3 months ago

Rocket Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

Rocket Pharmaceuticals Annual report: Q4 2025

Jan 14, 2026, 2:15 PM EST - 5 months ago

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-08T12:46:26.000Z - 5 months ago

Rocket Pharmaceuticals price target lowered to $5 from $7 at Morgan Stanley

Jan 5, 2026, 7:00 AM EST - 5 months ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 7:55 AM EST - 7 months ago

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:00 AM EST - 7 months ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 4:00 PM EST - 7 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 7:00 AM EST - 7 months ago

Rocket Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Rocket Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Rocket Pharmaceuticals Slides: Corporate Presentation

Oct 14, 2025, 7:00 AM EDT - 8 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 10, 2025, 4:00 PM EDT - 8 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 7:11 AM EDT - 9 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Sep 9, 2025, 9:15 AM EDT - 10 months ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 3:20 PM EDT - 10 months ago

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 11:02 AM EDT - 10 months ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 7:09 AM EDT - 10 months ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:00 AM EDT - 10 months ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 8, 2025, 2:16 PM EDT - 11 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Rocket Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Rocket Pharmaceuticals Quarterly report: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 17, 2025, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 9, 2025, 5:16 PM EDT - 1 year ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

tovlee Jun. 18 at 1:43 AM

$RCKT at least $10 by end of the year.

0 · Reply

topstockalerts Jun. 17 at 7:26 PM

$RCKT what looked ordinary this morning no longer does.

0 · Reply

iQuicky Jun. 17 at 5:57 PM

$INDP $CVKD $ARTV $REPL $RCKT investing in their future!

0 · Reply

Stephanovich7654568 Jun. 17 at 5:40 PM

$RCKT Blackrock is one of the biggest investment firm in USA. They are now the second largest holder of RCKT. They don't play with their money. They know what they are doing. 😉

1 · Reply

xXCronoSXx Jun. 17 at 4:47 PM

$RCKT

0 · Reply

geegor Jun. 17 at 4:03 PM

$RCKT large order inflows. Big fish loading.

0 · Reply

Cautiousamphybian Jun. 17 at 3:25 PM

$RCKT This is annoying. I'd only built about 10% of the position I wanted and have no idea why the share price is climbing so much today, seemingly no news. Anyone have any ideas?

4 · Reply

Diverstj981 Jun. 17 at 3:04 PM

$RCKT

0 · Reply

Wolfietrader Jun. 17 at 2:41 PM

$RCKT whu….huh?

0 · Reply

JunkPost Jun. 16 at 6:19 PM

1 · Reply

DinoMcnuggets Jun. 15 at 9:38 PM

$RCKT Company is trading below cash level with no debt, an approved product, and many catalysts in the future. Literally the most under appreciated biotech on wall street right now.

2 · Reply

xXCronoSXx Jun. 15 at 1:42 PM

$RCKT

0 · Reply

BinaryLogic Jun. 14 at 7:45 PM

$RCKT [Again] Start/build/add under $3.0 with 50-100% upside possible (IMO) on the successful execution, progress on its underlying pipeline. Kresladi for severe leukocyte adhesion deficiency-I (LAD-I) validates their underlying gene therapy technology, the PRV introduced $180M in non-dilutive capital, which extends the Cash runway here to 2029 (appx). No Debt. Danon disease readout(s) are likely the near term catalyst(s) here, as noted in my prior post. 50-100% upside from this level (IMO).

0 · Reply

Stephanovich7654568 Jun. 13 at 1:17 PM

$RCKT No worry. ❤️

1 · Reply

Xyz_83 Jun. 13 at 6:04 AM

$RCKT we are on the support and acumulation level.

0 · Reply

xXCronoSXx Jun. 12 at 3:24 PM

$RCKT

0 · Reply

xXCronoSXx Jun. 12 at 2:27 PM

$RCKT $SPCX

0 · Reply

xXCronoSXx Jun. 12 at 1:59 PM

$RCKT $SPCX

0 · Reply

Trader1141 Jun. 12 at 11:56 AM

$RCKT its got the word “rocket” in the name… algos will yake it to 🌕 $ASTS $SPCE $RKLB

0 · Reply

Trader1141 Jun. 12 at 11:55 AM

$RCKT What’s with the volume? Lol

0 · Reply

geegor Jun. 12 at 11:48 AM

$RCKT Change of plan, Rocket. 109m shares outstanding, just send us all a check for $1.65 per share as a gesture of goodwill instead 😂😂🤣 https://www.businesswire.com/news/home/20260612407717/en/Rocket-Pharmaceuticals-Announces-Closing-of-Sale-of-Rare-Pediatric-Disease-Priority-Review-Voucher-for-%24180-Million

0 · Reply

SusQSmallMouth Jun. 12 at 11:14 AM

$RCKT good day to announce a PR. Hopefully investors get confused and buy this instead of SpaceX 😅.

2 · Reply

Market Cap	305.74M
Revenue (ttm)	0.00
Net Income (ttm)	-223.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,537,400
Avg Vol	2,358,828
Day's Range	N/A - N/A
Shares Out	109.19M
Stochastic %K	88%
Beta	0.48
Analysts	Sell
Price Target	$9.39